ClinicalTrials.gg
Not yet recruitingNCT06906172REPAIRUpdated Apr 2, 2025

The REmission of Diabetes Using a PlAnt-based Weight Loss InteRvention (REPAIR) Trial

An interventional study of Plant-based intensive lifestyle intervention and Standard of Care in Diabetes Mellitus, sponsored by University of Toronto. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by University of Toronto · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Diabetes Mellitus by University of Toronto — 2 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus · University of Toronto.

Planned enrollment
4th of 24
160 · median 32
Started
2025
the only one that year
No phase
20 of 41
2 open now
Registered
40th of 41
by date

Among the 41 studies in Diabetes Mellitus by University of Toronto, this one is the 4th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2025, is one of 20 with no phase, and was the 40th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 41 studies in Diabetes Mellitus by University of Toronto are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Diabetes Mellitus by University of Toronto, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a plant-based intensive lifestyle intervention can achieve remission of diabetes. It will also learn if a plant-based intensive lifestyle intervention can achieve weight loss ≥15% of initial body weight.

The main questions it aims to answer are:

  • What proportion of participants achieved diabetes remission (normal blood sugar for at least 3 months without medication)?
  • What proportion of participants achieved ≥15% weight loss from their initial weight?
  • What is the impact on weight, body composition, blood pressure, blood sugars, cholesterol and inflammation levels?

Researchers will compare the plant-based intensive lifestyle intervention to the current standard of care.

Participants will be randomly placed into one of two groups:

  1. Standard of care, where they will continue their usual diabetes care with their health care providers
  2. Plant-based intensive lifestyle intervention, where they will follow a diet and exercise program

Participants in the standard of care will:

  • Continue with their usual diabetes care for 12 months
  • Attend clinic visits on 5 occasions over the 12 months
  • Allow study staff to take measurements (e.g. weight, blood pressure)
  • Provide blood samples
  • Track their food and exercise and complete questionnaires

Participants in the plant-based intensive lifestyle intervention will:

  • Follow a plant-based low calorie diet for 3 months followed by a calorie-balanced plant-based diet for 9 months
  • Participate in a 16-week exercise program
  • Attend clinic visits every 2-4 weeks over the 12 months
  • Allow study staff to take measurements (e.g. weight, blood pressure)
  • Provide blood sample
  • Track their food and exercise and complete questionnaires
03

Conditions studied

  • Diabetes Mellitus

Keywords

  • diabetes remission
  • weight loss
  • plant-based
  • diet
  • exercise
  • intensive lifestyle intervention
  • behavioural intervention
  • digital program
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 18 years;
  • Equal number of males and females;
  • Obese ( [BMI] and waist circumference using sex and ethnic-specific thresholds for obesity and significant abdominal adiposity);
  • Diagnosed with type 2 diabetes within the last 6 years;
  • Treated by non-insulin antihyperglycemic therapy;
  • Have an 6.0-10.0%;
  • Taking a stable dose of antihypertensive, antihyperglycemic, or antihyperlipidemic medications for ≥3-months, if applicable;
  • Have a family physician and an Ontario Health Card;

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes;
  • \<6.0% or >10%;
  • Recent weight loss (≥5 kg) in the last 6 months;
  • Treated with diet alone;
  • Treated with insulin;
  • Treated with GLP-1/GIP/glucagon receptor agonist therapies;
  • Treated with other anti-obesity drugs;
  • Eating disorder, substance abuse disorder, serious depression, psychiatric disorder;
  • Allergy or intolerance to soy;
  • Allergy or intolerance to peanuts, tree nuts and seeds (all three);
  • Pregnant or intending pregnancy;
  • Currently breastfeeding;
  • Bariatric or surgery in the last 6 months;
  • Major cardiovascular event in the last 6 months;
  • Kidney dysfunction;
  • Unstable or severe heart failure;
  • Major illness or chronic infection;
  • Atherosclerotic cardiovascular disease (ASCVD);
  • Chronic kidney disease (CKD);
  • Treated for cancer in the last 12 months;
  • Participating in another trial;
  • Told by a doctor to refrain from physical activity;
  • Any condition that would prevent you from following study procedures;
  • Family physician does not consent to your participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    plant-based intensive lifestyle intervention

    Participants will undergo a plant-based intensive lifestyle intervention targeting weight loss with the goal of achieving diabetes remission. All antihyperglycemic and/or antihypertensive medications will be stopped at the first visit as a safety measure. The interventions will be delivered at clinic visits at 2-4week intervals over the 52-weeks.

    Behavioral: Plant-based intensive lifestyle intervention

  • Active comparator
    standard of care

    Participants will continue to receive usual diabetes and obesity management with their health care provider(s) as per current Canadian clinical practice guidelines. Participants will attend clinic visits on 5 occasions over the 52-weeks.

    Other: Standard of Care

Interventions

  • BehavioralPlant-based intensive lifestyle intervention

    The plant-based intensive lifestyle intervention has 2 phases. The first 12-weeks is a weight loss phase consisting of a plant-based, high-plant protein energy restricted total diet replacement (TDR), psyllium-based fibre and complete multivitamin supplements, and vegetable bouillon, with the option of continuing with this phase up to week 20. The second phase is weight-loss maintenance beginning with an 8-week (weeks 12-20) stepped food reintroduction phase with partial meal replacement, progressing towards the 32-week (weeks 20-52) full food introduction phase. These phases focus on introducing a plant-based, high-plant protein, energy balanced, weight loss maintenance diet, which will be supported by a digital program. At weeks 12-28, a 16-week in-person structured exercise training program will be delivered followed by 2-weekly motivational phone calls until the 52-weeks. A 19-session, group-based, structured behavioural support program will be delivered throughout the study.

  • OtherStandard of Care

    Participants will continue to receive usual diabetes and obesity management as per current Canadian clinical practice guidelines. The management will continue to be delivered to participants through their family doctor, nurse practitioner, or diabetes care team with standard frequency of contact. Participants will attend clinic visits on 5 occasions (weeks 0, 12, 28, 40 and 52) and will receive motivational phone calls between visits to provide reminders regarding follow-up with their diabetes care providers.

06

What researchers measure

Primary outcomes

  1. Proportion achieving diabetes remission

    Proportion achieving diabetes remission, defined as an HbA1C \<6.5% for ≥3 months free of antihyperglycemic medications at 52 weeks.

    Time frame: From enrollment to the end of treatment at 52 weeks.

Secondary outcomes

  1. Key secondary: Proportion achieving ≥15% weight loss

    Proportion achieving ≥15% weight loss from baseline at 52 weeks.

    Time frame: From enrollment to the end of treatment at 52 weeks.

  2. Proportion achieving ≥10% and ≥5% weight loss from baseline change

    Proportion achieving ≥10% and ≥5% weight loss from baseline at 52 weeks

    Time frame: From enrollment to the end of treatment at 52 weeks

  3. Changes in measures of body composition

    Changes in body weight

    Time frame: From enrollment to the end of treatment at 52 weeks.

  4. Changes in measures of body composition

    Changes in body mass index

    Time frame: From enrollment to the end of treatment at 52 weeks.

  5. Changes in measures of body composition

    Changes in waist circumference

    Time frame: From enrollment to the end of treatment at 52 weeks.

  6. Changes in measures of body composition

    Changes in body fat

    Time frame: From enrollment to the end of treatment at 52 weeks.

  7. Changes in measures of body composition

    Changes in lean body mass

    Time frame: From enrollment to the end of treatment at 52 weeks.

  8. Proportion experiencing relapse

    Proportion experiencing relapse, defined as having achieved remission at any time during the trial but having an HbA1c ≥6.5% at 52 weeks.

    Time frame: From enrollment to the end of treatment at 52 weeks.

  9. Changes in functional tests

    Changes in sit-stand chair

    Time frame: From enrollment to the end of treatment at 52 weeks.

  10. Changes in functional tests

    Changes in grip test

    Time frame: From enrollment to the end of treatment at 52 weeks.

  11. Changes in glycemic control

    Changes in HbA1c

    Time frame: From enrollment to the end of treatment at 52 weeks.

  12. Changes in glycemic control

    Changes in fasting plasma glucose

    Time frame: From enrollment to the end of treatment at 52 weeks.

  13. Changes in blood lipids

    Changes in LDL-cholesterol, non-HDL cholesterol, HDL-cholesterol, total cholesterol and triglycerides.

    Time frame: From enrollment to the end of treatment at 52 weeks.

  14. Changes in blood pressure

    Changes in systolic and diastolic blood pressure.

    Time frame: From enrollment to the end of treatment at 52 weeks.

  15. Changes in inflammation

    Changes in c-reactive protein (CRP)

    Time frame: From enrollment to the end of treatment at 52 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All outcomes listed will be shared in an anonymous/de-identified format.

Supporting information: Study protocol

Time frame: IPD and supporting information will be available after the anticipated study completion date from January 2030 and will remain for 30 years until January 2060.

Access criteria: IPD data will be accessible though the University of Toronto Dataverse (https://borealisdata.ca/dataverse/toronto). The metadata record of our dataset will be public, however access to the data will be restricted. Users will need to request access using the contact information provided in order to view and download our restricted files.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2028, 39 months later.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 39 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Apr 2, 2025
StartEst.
Sep 2025
Primary completionEst.
Dec 19, 2028
CompletionEst.
Dec 30, 2029
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06906172
Responsible party
Laura Chiavaroli (Assistant Professor, University of Toronto) — Principal investigator
First posted
Apr 2, 2025
Start date
Sep 2025 (estimated)
Primary completion
Dec 19, 2028 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Apr 2, 2025

Study contacts

Research Study Coordinator
Contact
REPAIRtrial@unityhealth.to
416-867-7474
Dr. Laura Chiavaroli, MSc, PhD
principal investigator · University of Toronto
Dr. John L Sievenpiper, MD, PhD, FRCPC
principal investigator · University of Toronto, St. Michael's Hospital
Dr. David JA Jenkins, OC, MD, PhD, DSC, FRCP, FRCPSC
principal investigator · University of Toronto, St. Michael's Hospital
Dr. Cyril WC Kendall, PhD
principal investigator · University of Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion